Nerandomilast (BI 1015550) attenuating pulmonary fibrosis in a mouse model of rheumatoid arthritis-associated interstitial lung disease by modulating the TGF-β1/PI3K/Akt signaling pathway. (PubMed, J Thorac Dis) - Sep 12, 2026 - "A total of 20 male DBA/1 mice (a classic collagen-induced arthritis-susceptible strain) aged 8 weeks were randomly assigned to four groups: control (n=3), RA-ILD (n=5), nerandomilast (BI 1015550) (n=6), and nintedanib (n=6). Furthermore, the nerandomilast group showed significantly decreased p-PI3K/PI3K and p-Akt/Akt expression ratios compared with the RA-ILD group (P<0.05). Nerandomilast exerts significant protective effects against pulmonary inflammation and fibrosis in RA-ILD mice, potentially through the downregulation of TNF-α expression and modulation of the TGF-β1/PI3K/Akt signaling pathway."
Journal • Preclinical • Fibrosis • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • MMP3 • TGFB1 • TNFA
|
|
Lin Tang; Xi Liu; Xiaohong Wang; Xue Zhong
|